NCT06399757 - A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

June 18, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

May 31, 2027

Conditions

Colorectal CancerCholangiocarcinomaAppendiceal AdenocarcinomaPancreatic AdenocarcinomaGastric AdenocarcinomaEndometrial AdenocarcinomaTriple Negative Breast CancerOvarian CancerProstate Cancer

Interventions

DRUG

APL-5125

APL-5125 is an oral drug (capsule) taken daily in 28-day cycles

Trial Locations (9)

27710

RECRUITING

Duke Cancer Institute, Durham

28078

RECRUITING

Carolina BioOncology Institute, Huntersville

29425

RECRUITING

Medical University of South Carolina, Charleston

34232

RECRUITING

Florida Cancer Specialists & Research Institute, Sarasota

48109

RECRUITING

University of Michigan, Ann Arbor

75251

RECRUITING

Mary Crowley Cancer Research, Dallas

78229

RECRUITING

NEXT Oncology- San Antonio, San Antonio

91010

RECRUITING

City of Hope, Duarte

92618

RECRUITING

City of Hope Orange County Lennar Foundation Cancer Center, Irvine